Table 2 Nordic treatment regimen for MCL

No.

41

160

160

Median age (range), y

56 (38–65)

56 (32–65)

58 (28–65)

MIPI score (%)

Low/Int/High

8/46/23/23^a

51/26/23

48/31/21

Induction

Maxi-CHOP21^a

R-Maxi-CHOP21 alternating with R-HD-Ara-c

R-Maxi-CHOP21 alternating with R-HD-Ara-c

Intensification therapy

BEAM/BEAC+ASCT

BEAM/BEAC+ASCT+/− rituximab

BEAM/BEAC+ (Zevalin, if<CR) + ASCT

ORR(%)

96

96

97

CR (%)

89

54

82

Follow-up (ys)

2.8

11.4

4.4

mPFS (ys)

4-y FFS, 20%

8.5

NR (4-y PFS, 71%)

mOS (ys)

4-y OS, 61%

12.7

NR (4-y OS, 78%)

TRM (%)

2

7

6

Second malignancy(%)

7

6

4